Scar tissue is regularly mistaken for cancer on medical imaging, and the confusion runs in both directions. Dense, irregular scar tissue can look nearly identical to a malignant tumor on a mammogram, CT scan, or MRI, triggering false alarms, additional testing, and real anxiety for patients. The problem shows up across the body, from breast tissue after surgery to lungs treated with radiation to the brain after tumor removal. Understanding where and why this happens matters because it shapes how your doctors interpret scans and when they decide a biopsy is truly necessary.
Breast Scars and Mammography
The breast is where scar-versus-cancer confusion comes up most often in routine clinical practice. Scar tissue inside the breast, especially when it sits next to fatty tissue, frequently shows up on mammograms as a poorly defined mass with spiky, irregular edges. Radiologists call those “spiculated” margins, and they are one of the classic warning signs for breast cancer. Scars can also show up as areas of architectural distortion or clusters of tiny calcium deposits, both of which overlap with how carcinomas present. Because the two look so similar, false-positive cancer diagnoses from intramammary scars are a recognized problem in breast imaging.1PubMed. Intramammary scar tissue: a mimic of the mammographic appearance of carcinoma
This overlap is especially frustrating for women who have already had breast surgery. If you had a lumpectomy or even a breast biopsy, the healing process creates fibrous tissue right where radiologists are looking most carefully for signs of recurrence. The scar can pull on surrounding tissue and cause skin thickening or retraction, which are also red flags for cancer on a mammogram. The result is that follow-up imaging after breast surgery requires an experienced eye and usually more than one type of scan.
Fat Necrosis as a Particularly Tricky Mimic
Fat necrosis deserves its own mention because it is one of the most common benign conditions that gets confused for breast cancer. When fatty tissue in the breast is injured, whether from surgery, radiation, trauma, or even something as mundane as a seatbelt injury, it can die and trigger an inflammatory response. The resulting lump is completely benign, but on imaging it can look alarming. Fat necrosis has been called a “consultant’s conundrum” because it mimics breast cancer across nearly every imaging technique: mammography, ultrasound, CT, and MRI.2Frontiers in Oncology. Fat necrosis: A consultant’s conundrum
The range of appearances is what makes fat necrosis so problematic. Sometimes it shows up as a classic oil cyst or benign-looking calcification that a radiologist can confidently dismiss. Other times, it appears as a solid-looking mass, an area of distorted architecture, or an asymmetric density, all of which look suspicious.3PubMed Central. Fat Necrosis of the Breast: A Pictorial Review of the Mammographic, Ultrasound, CT, and MRI Findings with Histopathologic Correlation The way it looks also changes over time as the damaged tissue evolves through different stages of healing and calcification, meaning the same lesion can look benign on one scan and worrisome six months later.4PubMed. Fat necrosis in the breast: a multimodality imaging review of its natural course with different aetiologies For patients, this often translates to being called back for additional imaging or even a biopsy for something that turns out to be harmless.
Post-Radiation Scarring in the Lungs
The confusion between scar tissue and cancer is particularly acute in the lungs after radiation treatment. Stereotactic body radiation therapy (SBRT), a focused, high-dose radiation treatment for early-stage lung cancer, is effective at killing tumors but leaves behind a trail of tissue changes that look a lot like cancer on CT scans. Early after treatment, the irradiated area typically shows up as a hazy or solid patch. Over time, this evolves into fibrotic scarring, which can persist for years and take on a dense, mass-like appearance that is genuinely difficult to tell apart from a tumor that has come back.5European Journal of Radiology. Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: A timeline and pattern of CT changes
A systematic review of the literature on post-SBRT imaging found that the acute changes mostly look like areas of consolidation or ground-glass opacity, while later changes settle into patterns of fibrosis that can continue evolving beyond two years.6PubMed. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)–can we distinguish recurrence from fibrosis? A systematic review of the literature The most reliable warning sign for actual recurrence, rather than just scarring, was an opacity that kept growing at the 12-month mark. That feature had good sensitivity but was far from perfect, and researchers have found that combining multiple suspicious features on a scan improves accuracy.7PubMed Central. Radiological differential diagnosis between fibrosis and recurrence after stereotactic body radiation therapy (SBRT) in early stage non-small cell lung cancer (NSCLC) The practical takeaway is that a single scan showing a mass in a previously irradiated lung does not necessarily mean the cancer has returned, but it does mean close surveillance.
The Brain After Tumor Treatment
In the brain, the equivalent problem is called radiation necrosis. After radiation treatment for a brain tumor, the treated area can develop a mass of dead, scarred tissue that lights up on an MRI in much the same way a regrowing tumor would. Both produce swelling, both enhance with contrast dye, and both can cause new or worsening neurological symptoms. For patients, the difference between “your cancer is back” and “this is expected scarring from treatment” is enormous, but on conventional MRI the two can look almost identical.8PubMed Central. Brain Tumor Recurrence vs. Radiation Necrosis Classification and Patient Survivability Prediction
Radiation necrosis is treated very differently from recurrent cancer. Necrosis may be managed with steroids or observation, while a growing tumor requires surgery or additional therapy. Getting the wrong answer can mean either subjecting a patient to unnecessary surgery or missing a cancer that needs immediate treatment. Researchers have been developing computational tools, including machine-learning models that analyze fine-grained MRI features, to improve the distinction. One such model achieved strong performance in telling the two apart, but these tools are still working their way into routine clinical use.8PubMed Central. Brain Tumor Recurrence vs. Radiation Necrosis Classification and Patient Survivability Prediction
Rectal and Pelvic Scarring After Cancer Treatment
Rectal cancer treatment typically involves some combination of surgery, radiation, and chemotherapy. After treatment, the pelvis fills in with scar tissue right where the original tumor was, and follow-up imaging needs to determine whether any residual or regrowing mass is cancer or just fibrosis. Standard MRI sequences can struggle with this because both scar tissue and tumor appear as soft-tissue masses that may enhance with contrast.
Diffusion-weighted MRI has proven especially useful here. This technique measures how freely water molecules move through tissue. Cancer cells are tightly packed, so water movement is restricted, producing lower values on a measurement called the apparent diffusion coefficient (ADC). Scar tissue, being more loosely organized, lets water move more freely and produces higher ADC values. One study found that the average ADC of recurrent rectal tumor was significantly lower than that of scar tissue, and using a specific ADC cutoff achieved about 93% sensitivity and 91% specificity in telling the two apart.9PubMed. Differentiating locally recurrent rectal cancer from scar tissue: Value of diffusion-weighted MRI That level of accuracy is strong, but it still means roughly one in ten cases gets the wrong initial read.
When the Confusion Runs the Other Way
Most of this article has focused on scar tissue being mistaken for cancer. But the reverse happens too, and it can be more dangerous. Certain cancers grow in a way that closely resembles benign scarring, and a pathologist or clinician who is not specifically looking for malignancy can miss them.
A striking example is desmoplastic squamous cell carcinoma of the skin. This unusual variant produces large amounts of fibrous tissue and contains cells that look deceptively bland under the microscope, mimicking a harmless scar or a benign growth like a dermatofibroma. A study of six such cases emphasized that recognizing this entity is essential because it can easily be misdiagnosed as a benign scarring process.10The American Journal of Dermatopathology. Desmoplastic/Spindle Cell Squamous Cell Carcinoma of the Skin. A Diagnostically Challenging Tumor Mimicking a Scar: Clinicopathologic and Immunohistochemical Study of 6 Cases If a biopsy specimen is too shallow or the pathologist is not alert to this variant, the cancer can go undetected.
Similarly, inflammatory myofibroblastic tumors are rare growths composed of spindle-shaped cells mixed with inflammatory cells. They can occur almost anywhere in the body but are most common in the lungs and abdominal cavity. On imaging, they frequently simulate a malignant tumor, but under the microscope they can also be confused with reactive scar tissue because of their bland-looking cellular components. Surgical removal is typically needed both to treat the tumor and to establish the correct diagnosis.11PubMed Central. Inflammatory myofibroblastic tumor mimics an abdominal neoplasm
How Doctors Sort It Out
Given how often scar tissue and cancer overlap in appearance, radiologists and oncologists rely on a combination of tools rather than any single test. The approach depends on the body site and the clinical context, but a few strategies come up repeatedly.
Diffusion-weighted MRI, as described in the rectal cancer context, works across multiple body sites. In the breast, the ADC values of recurrent tumors are consistently lower than those of surgical scars, and this difference has been shown to be statistically significant.12European Journal of Radiology. DWI in breast MRI: Role of ADC value to determine diagnosis between recurrent tumor and surgical scar in operated patients The same principle applies in the head and neck, where ADC values help distinguish post-treatment scarring from recurrent tumor.13Magnetic Resonance Imaging Clinics of North America. Diffusion-Weighted Imaging of the Head and Neck For the prostate after focal therapy, functional MRI techniques including diffusion-weighted imaging and dynamic contrast-enhanced sequences have shown promise in detecting local recurrence amid post-treatment changes.14PubMed. Role of MRI in follow-up after focal therapy for prostate carcinoma
PET scans, which detect areas of high metabolic activity, are another common tool. Cancers tend to consume glucose at a high rate and light up brightly on a PET scan, while scar tissue generally does not. But PET scans are not foolproof. Inflammatory processes, infection, and even foreign materials like surgical mesh can produce false positives. In one study of patients being evaluated for peritoneal spread of colorectal cancer, false-positive PET results were traced back to things like surgical mesh from a prior hernia repair and foreign body granulomas, both of which are forms of scar tissue or inflammatory reaction.15Journal of Visceral Surgery. Pitfalls and mimickers on 18F-FDG-PET/CT in peritoneal carcinomatosis from colorectal cancer: An analysis from 37 patients
When imaging alone cannot settle the question, biopsy remains the definitive answer. A tissue sample examined under the microscope can usually distinguish cancer cells from fibrous scar tissue, although even this can be challenging in certain settings, as the desmoplastic carcinoma example illustrates. In practice, many clinicians prefer to monitor ambiguous findings over time with serial imaging, looking for changes in size or character, rather than biopsy every uncertain finding.
Artificial Intelligence as a Sorting Tool
One of the more promising developments is the use of AI models trained specifically on the scar-versus-recurrence problem. A deep learning system called SCAR-Net was developed using more than 34,000 ultrasound images from over 5,700 patients across four hospitals, all focused on distinguishing postoperative breast scars from recurrent cancer. When radiologists used the tool alongside their own judgment, their diagnostic accuracy jumped substantially: the area under the curve improved from roughly 0.81–0.82 to about 0.94, sensitivity rose from around 78% to over 93%, and specificity climbed from about 84–87% to roughly 94–95%.16PubMed Central. SCAR-Net-assisted ultrasound diagnosis of postoperative scars and recurrent lesions in breast cancer Those are large improvements. In practical terms, that kind of performance could substantially reduce unnecessary biopsies while catching more true recurrences earlier.
AI tools like this are not yet standard in most hospitals, and they work best in the specific settings they were trained for. A model trained on breast ultrasound images would not help with lung CT scans or brain MRIs. But the basic approach, training algorithms on large datasets of confirmed scar-versus-cancer cases, is being applied across imaging specialties. The challenge has always been that radiologists reading scans are working with visual patterns that genuinely overlap between the two conditions. Having a computational system that can detect subtle features invisible to the human eye adds a useful layer.
What This Means If You Are a Patient
If you have had surgery or radiation therapy for any cancer, your follow-up imaging will almost certainly show changes in the treated area. Scarring, inflammation, and tissue remodeling are normal parts of healing, and they can look worrisome on a scan even when nothing is wrong. Knowing this can help you prepare for the possibility of a callback or an additional test without assuming the worst.
A few things are worth keeping in mind. First, the timing of your scan matters. In the lungs, for example, fibrotic changes evolve over two or more years after radiation, and a scan taken during this window is more likely to be ambiguous than one taken later when the scarring has stabilized. Second, your radiologist’s access to your surgical and treatment history makes a real difference. A mass that appears alarming in isolation may be easily explained when the radiologist knows exactly where and when you had surgery. Always make sure your imaging center has your prior scans and treatment records. Third, a finding that is “indeterminate” or “needs further evaluation” on a radiology report does not mean cancer. It means the radiologist could not confidently say it was benign based on that one test and wants more information. That information might come from a different type of scan, a short-interval follow-up to check for growth, or a biopsy.
Keloid Scars and an Unexpected Cancer Connection
Keloids, the raised, often thick scars that grow beyond the boundaries of the original wound, are a different kind of scar tissue entirely. They are not typically confused with cancer on imaging, but they do have an unexpected relationship with cancer risk. A large study of over 17,000 patients with keloids found that about 5% developed cancer during the study period. The overall cancer risk was roughly 1.5 times higher in the keloid group compared to controls, and for skin cancer specifically, the risk was about 1.7 times higher. Among men with keloids, the relative risk for skin cancer climbed to about twice that of the comparison group.17Scientific Reports. Risk of cancer development in patients with keloids
The reasons for this association are not fully settled. Keloids involve persistent inflammation and abnormal cell growth pathways, and chronic inflammation is a recognized driver of cancer development in other contexts. This does not mean that having a keloid causes cancer, and the absolute risk increase is modest. But it is a reminder that scar tissue is not always biologically inert. The same cellular processes that produce exuberant scarring may, in some people, overlap with the processes that lead to malignancy. For anyone with keloid-prone skin, routine skin checks remain a reasonable practice for reasons beyond the scars themselves.